Skip to main content
41°
Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Natera, Inc.
< Previous
1
2
3
Next >
Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications
April 22, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
April 11, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients
April 08, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
April 05, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
April 01, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
March 18, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease
March 14, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers
March 12, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS Plan
March 07, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera to Participate in March Investor Conferences
February 29, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Reports Fourth Quarter and Full Year 2023 Financial Results
February 28, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces Next Phase of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure Tests
February 27, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Medicare Extends Coverage of Natera’s Signatera™ MRD Test to Ovarian Cancer and Neoadjuvant Breast Cancer
February 26, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces Fourth Quarter and Fiscal 2023 Earnings Conference Call
February 20, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
New Study Validates Signatera™ in Endometrial Cancer
February 05, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
New Publication Demonstrates Signatera’s Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer
January 30, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Jury Rules in Favor of Natera in Patent Infringement Lawsuit Against CareDx; Awards $96.3 Million in Damages to Natera in Lost Profits and Past Royalties
January 29, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Nature Medicine Publishes Two Studies Highlighting Signatera’s Clinical Utility in Patients with Gastrointestinal Malignancies
January 25, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Acquires Reproductive Health Assets from Invitae
January 22, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera to Present New Data from the CIRCULATE-Japan and BESPOKE CRC Studies at ASCO GI 2024 Supporting Signatera’s Clinical Utility in CRC
January 18, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Provides Update on Ravgen Trial
January 16, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces Preliminary Fourth Quarter and Full Year 2023 Revenues
January 09, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
December 29, 2023
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Wins Preliminary Injunction in Patent Infringement Lawsuit Against NeoGenomics’ RaDaR Test
December 27, 2023
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces New Study Highlighting the Benefits of Signatera’s Unique Method of Quantifying ctDNA
December 21, 2023
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Delaware Court Denies CareDx’s Motion for Summary Judgment on Two Natera Patents
December 11, 2023
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023
December 06, 2023
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces Real-World Data Collaboration with Merck
November 14, 2023
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Reports Third Quarter 2023 Financial Results
November 08, 2023
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer
November 08, 2023
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.